Combination of immune stimulating adjuvants with poly(lactide-co-glycolide) microspheres enhances the immune response of vaccines

Vaccine

Volumn 30, Issue 3, 2012, Pages 589-596

  Salvador, Aiala ^a,b   Igartua, Manoli ^a,b   Hernández, Rosa M ^a,b   Pedraz, José Luis ^a,b  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b BIOMATERIALES Y NANOMEDICINA CIBER BBN   (Spain)

Author keywords

Galactosylceramide; Adjuvant; MPLA; PLGA; Poly(I:C); Vaccine

Indexed keywords

ADJUVANT; ALPHA GALACTOSYLCERAMIDE; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; MICROSPHERE; PHOSPHORYL LIPID A; POLYGLACTIN;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENCAPSULATION; FEMALE; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES; DRUG CARRIERS; FEMALE; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; MICROSPHERES; POLYGLACTIN 910; SERUM ALBUMIN, BOVINE; VACCINES;

EID: 84355165224     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.11.057     Document Type: Article

References (38)

1. Perrie Y., Mohammed A.R., Kirby D.J., McNeil S.E., Bramwell V.W. Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens. International Journal of Pharmaceutics 2008, 364:272-280.
2. Salvador A., Igartua M., Hernández R.M., Pedraz J.L. An overview on the field of micro- and nanotechnologies for synthetic peptide-based vaccines. Journal of Drug Delivery 2011.
3. Look M., Bandyopadhyay A., Blum J., Fahmy T. Application of nanotechnologies for improved immune response against infectious diseases in the developing world. Advanced Drug Delivery Reviews 2010, 62:378-393.
4. Mundargi R.C., Babu V.R., Rangaswamy V., Patel P., Aminabhavi T.M. Nano/micro technologies for delivering macromolecular therapeutics using poly(d,l-lactide-co-glycolide) and its derivatives. Journal of Controlled Release 2008, 125:193-209.
5. Schlosser E., Mueller M., Fischer S., Basta S., Busch D.H., Gander B., et al. TLR ligands and antigen need to be coencapsulated into the same biodegradable microsphere for the generation of potent cytotoxic T lymphocyte responses. Vaccine 2008, 26:1626-1637.
6. Salaun B., Greutert M., Romero P. Toll-like receptor 3 is necessary for dsRNA adjuvant effects. Vaccine 2009, 27:1841-1847.
7. Salem M.L., El-Naggar S.A., Kadima A., Gillanders W.E., Cole D.J. The adjuvant effects of the toll-like receptor 3 ligand polyinosinic-cytidylic acid poly (I:C) on antigen-specific CD8+ T cell responses are partially dependent on NK cells with the induction of a beneficial cytokine milieu. Vaccine 2006, 24:5119-5132.
8. Wischke C., Zimmermann J., Wessinger B., Schendler A., Borchert H-H., Peters J.H., et al. Poly(I:C) coated PLGA microparticles induce dendritic cell maturation. International Journal of Pharmaceutics 2009, 365:61-68.
9. Cui Z., Qiu F. Synthetic double-stranded RNA poly(I:C) as a potent peptide vaccine adjuvant: therapeutic activity against human cervical cancer in a rodent model. Cancer Immunology, Immunotherapy 2006, 55:1267-1279.
10. Verdijk R.M., Mutis T., Esendam B., Kamp J., Melief C.J.M., Brand A., et al. Polyriboinosinic polyribocytidylic acid (Poly(I:C)) induces stable maturation of functionally active human dendritic cells. The Journal of Immunology 1999, 163:57-61.
11. Persing D.H., Coler R.N., Lacy M.J., Johnson D.A., Baldridge J.R., Hershberg R.M., et al. Taking toll: lipid A mimetics as adjuvants and immunomodulators. Trends in Microbiology 2002, 10:s32-s37.
12. Quintilio W., Kubrusly F.S., Iourtov D., Miyaki C., Sakauchi M.A., Lúcio F., et al. Bordetella pertussis monophosphoryl lipid A as adjuvant for inactivated split virion influenza vaccine in mice. Vaccine 2009, 27:4219-4224.
13. Chong C.S.W., Cao M., Wong W.W., Fischer K.P., Addison W.R., Kwon G.S., et al. Enhancement of T helper type 1 immune responses against hepatitis B virus core antigen by PLGA nanoparticle vaccine delivery. Journal of Controlled Release 2005, 102:85-99.
14. Elamanchili P., Diwan M., Cao M., Samuel J. Characterization of poly(lactic-co-glycolic acid) based nanoparticulate system for enhanced delivery of antigens to dendritic cells. Vaccine 2004, 22:2406-2412.
15. Kawano T., Cui J., Koezuka Y., Toura I., Kaneko Y., Motoki K., et al. CD1d-restricted and TCR-mediated activation of Vα14 NKT cells by glycosylceramides. Science 1997, 278:1626-1629.
16. Cerundolo V., Barral P., Batista F.D. Synthetic iNKT cell-agonists as vaccine adjuvants-finding the balance. Current Opinion in Immunology 2010, 22:417-424.
17. Fujii S., Motohashi S., Shimizu K., Nakayama T., Yoshiga Y., Taniguchi M. Adjuvant activity mediated by iNKT cells. Seminars in Immunology 2010, 22:97-102.
18. Thapa P., Zhang G., Xia C., Gelbard A., Overwijk W.W., Liu C., et al. Nanoparticle formulated alpha-galactosylceramide activates NKT cells without inducing anergy. Vaccine 2009, 27:3484-3488.
19. Gombotz W.R., Wee S. Protein release from alginate matrices. Advanced Drug Delivery Reviews 1998, 3:267-285.
20. Mata E., Igartua M., Patarroyo M.E., Pedraz J.L., Hernández R.M. Enhancing immunogenicity to PLGA microparticulate systems by incorporation of alginate and RGD-modified alginate. European Journal of Pharmaceutical Sciences 2011, (44):32-40.
21. Mata E., Carcaboso A.M., Hernández R.M., Igartua M., Corradin G., Pedraz J.L. Adjuvant activity of polymer microparticles and Montanide ISA 720 on immune responses to Plasmodium falciparum MSP2 long synthetic peptides in mice. Vaccine 2007, 25:877-885.
22. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. Journal of Immunological Methods 1983, 65:55-63.
23. Rosas J., Hernández R., Gascón A., Igartua M., Guzman F., Patarroyo M., et al. Biodegradable PLGA microspheres as a delivery system for malaria synthetic peptide SPf66. Vaccine 2001, 19:4445-4451.
24. DeBenedictis C., Joubeh S., Zhang G., Barria M., Ghohestani R.F. Immune functions of the skin. Clinics in Dermatology 2001, 19:573-585.
25. Clawson C., Huang C-T., Futalan D., Martin Seible D., Saenz R., Larsson M., et al. Delivery of a peptide via poly(d,l-lactic-co-glycolic) acid nanoparticles enhances its dendritic cell-stimulatory capacity. Nanomedicine: Nanotechnology, Biology and Medicine 2010, 6:651-661.
26. Monie T.P., Bryant C.E., Gay N.J. Activating immunity: lessons from the TLRs and NLRs. Trends in Biochemical Sciences 2009, 34:553-561.
27. Blanco P., Palucka A.K., Pascual V., Banchereau J. Dendritic cells and cytokines in human inflammatory and autoimmune diseases. Cytokine & Growth Factor Reviews 2008, 19:41-52.
28. Jhunjhunwala S., Raimondi G., Thomson A.W., Little S.R. Delivery of rapamycin to dendritic cells using degradable microparticles. Journal of Controlled Release 2009, 133:191-197.
29. Walter E., Dreher D., Kok M., Thiele L., Kiama S.G., Gehr P., et al. Hydrophilic poly(lactide-co-glycolide) microspheres for the delivery of DNA to human-derived macrophages and dendritic cells. Journal of Controlled Release 2001, 76:149-168.
30. Thomas C., Gupta V., Ahsan F. Influence of surface charge of PLGA particles of recombinant hepatitis B surface antigen in enhancing systemic and mucosal immune responses. International Journal of Pharmaceutics 2009, 379:41-50.
31. Zolnik B.S., Burgess D.J. Evaluation of in vivo-in vitro release of dexamethasone from PLGA microspheres. Journal of Controlled Release 2008, 127:137-145.
32. Mata E., Igartua M., Hernández R.M., Rosas J.E., Patarroyo M.E., Pedraz J.L. Comparison of the adjuvanticity of two different delivery systems on the induction of humoral and cellular responses to synthetic peptides. Drug Delivery 2010, 0:1-10.
33. Longhi M.P., Trumpfheller C., Idoyaga J., Caskey M., Matos I., Kluger C., et al. Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant. Journal of Experimental Medicine 2009, 206:1589-1602.
34. Sauerwein R.W. Clinical malaria vaccine development. Immunology Letters 2009, 122:115-117.
35. Steinman R.M. Dendritic cells in vivo: a key target for a new vaccine science. Immunity 2008, 29:319-324.
36. Fujii S.-i., Shimizu K., Hemmi H., Fukui M., Bonito A.J., Chen G., et al. Glycolipid α-C-galactosylceramide is a distinct inducer of dendritic cell function during innate and adaptive immune responses of mice. Proceedings of the National Academy of Sciences 2006, 103:11252-11257.
37. Hermans I.F., Silk J.D., Gileadi U., Masri S.H., Shepherd D., Farrand K.J., et al. Dendritic cell function can be modulated through cooperative actions of TLR ligands and invariant NKT cells. The Journal of Immunology 2007, 178:2721-2729.
38. Hafner A.M., Corthésy B., Textor M., Merkle H.P. Tuning the immune response of dendritic cells to surface-assembled poly(I:C) on microspheres through synergistic interactions between phagocytic and TLR3 signaling. Biomaterials 2011, 32:2651-2661.